Blackstone Adapts Funds for Credit Market Changes
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy BX?
Source: Newsfilter
- Earnings Growth: Blackstone reported rising earnings in its latest financial results, despite increasing investor concerns about private debt, demonstrating the company's resilience and profitability in uncertain market conditions.
- Market Expectations: CEO Stephen Schwarzman indicated that base rates are expected to decline once the impact of the Iran war subsides, while default rates are anticipated to rise from historic lows, reflecting potential market risks.
- Fund Design Strategy: Blackstone has designed its funds with credit cycle changes in mind, employing low leverage, high current income, and significant reserves for potential future losses, which enhances investor confidence.
- Long-Term Return Confidence: Schwarzman emphasized Blackstone's strong confidence in its ability to achieve premium returns in liquid markets, indicating the company's strategic adaptability and foresight in complex economic environments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BX
Wall Street analysts forecast BX stock price to rise
12 Analyst Rating
5 Buy
7 Hold
0 Sell
Moderate Buy
Current: 119.830
Low
166.00
Averages
176.60
High
205.00
Current: 119.830
Low
166.00
Averages
176.60
High
205.00
About BX
Blackstone Inc. is an alternative asset manager. Its asset management includes global investment strategies focused on real estate, private equity, infrastructure, life sciences, growth equity, credit, real assets, secondaries, and hedge funds. Its Real Estate segment comprises its management of opportunistic real estate funds, Core+ real estate funds, and real estate debt strategies. Its Private Equity segment includes its management of flagship Corporate Private Equity funds, sector and geographically focused Corporate Private Equity funds, core private equity funds, an investment platform, and others. Its Credit & Insurance segment consists of Blackstone Credit & Insurance, which is organized into three overarching strategies: private corporate credit, liquid corporate credit and infrastructure and asset-based credit. Its Multi-Asset Investing segment is organized into four investment platforms: Absolute Return, Multi-Strategy, Total Portfolio Management, and Public Real Assets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Blackstone's $400 Million Investment in Teva: A Strategic Bet
- Investment Scale and Strategic Significance: Blackstone Life Sciences' $400 million investment in Teva Pharmaceuticals in March 2023 reflects strong confidence in the new drug duvakitug, representing not just financial backing but a significant bet on Teva's future development.
- Drug Potential and Clinical Progress: Duvakitug, a monoclonal antibody targeting TL1A, is currently undergoing Phase 3 clinical trials for ulcerative colitis and Crohn's disease, with promising Phase 2 results showing durable efficacy over 44 weeks, indicating a broad market potential.
- Teva's Transformation and Market Recognition: Teva has evolved from a mere generic drug manufacturer to a leader in biopharmaceutical innovation, with credit rating agencies upgrading its rating to BB+, reflecting market confidence in its transformation.
- Opportunities and Risks for Investors: Blackstone's investment not only provides Teva with financial support but may also yield milestone payments and low single-digit royalties on global sales, suggesting that while risk-averse investors might hesitate, aggressive investors could find significant value in Teva, especially if duvakitug succeeds as anticipated.
See More
Blackstone Commits $400 Million to Teva's Drug Development
- Significant Investment: Blackstone Life Sciences has committed $400 million to Teva Pharmaceuticals to support the development of its autoimmune disease drug, duvakitug, reflecting confidence in Teva's future and showcasing Blackstone's strategic positioning in the biopharmaceutical sector.
- Clinical Trial Progress: Duvakitug is currently undergoing Phase 3 clinical trials aimed at treating ulcerative colitis and Crohn's disease, with promising Phase 2 results indicating durable efficacy over 44 weeks, suggesting substantial market potential and the possibility of becoming a best-in-class therapy.
- Credit Rating Upgrade: Following Blackstone's investment, credit rating agencies have begun to recognize Teva's turnaround, with S&P Global upgrading Teva's credit rating from BB to BB+ in December 2025, reflecting a stable outlook and market optimism about its future development.
- Positive Market Outlook: Analysts are generally bullish on Teva, with 12 out of 13 surveyed analysts rating the stock as a
See More
Shell Sells Stake in LNG Canada Project Amid Bidding War
- Bidding War Intensifies: Apollo Global Management, Blackstone, and KKR are competing to acquire a significant stake in Shell's LNG Canada project, with the deal expected to be valued well over $10 billion, potentially reaching $15 billion, indicating strong market interest in LNG projects.
- Shell's Strategic Shift: The sale will allow Shell to divest a portion of its 40% stake in LNG Canada while funding its $16.4 billion acquisition of Canadian natural gas producer ARC Resources, thereby optimizing its asset portfolio.
- Significant Market Potential: The LNG Canada project, which began production in June, is the first major liquefied natural gas facility in North America with direct access to the Pacific, enabling direct shipments to Asia, the largest market for super-cooled fuel, and is expected to attract more investor attention.
- Clear Transaction Structure: Shell plans to sell both the first and second phases of the project to a single bidder rather than splitting them, a strategy that will help streamline the transaction process and enhance buyer confidence.
See More
Apollo, Blackstone, KKR Compete for LNG Canada Stake
- Bidding Landscape: Apollo, Blackstone, and KKR are competing to acquire a 40% stake in Shell's LNG Canada project, with the deal expected to be valued well above $10 billion and potentially reaching $15 billion, providing Shell with crucial capital to support its expansion plans.
- Strategic Implications: The sale will allow Shell to focus on higher-return businesses after its $16.4 billion acquisition of Canadian natural gas producer ARC Resources, while attracting new capital to further develop the LNG project, enhancing its competitive position in the North American market.
- Insurance Capital Utilization: All three firms are leveraging capital from their insurance businesses—Apollo's Athene, Blackstone Credit & Insurance, and KKR's Global Atlantic—to bolster their bids, reflecting the asset management industry's ongoing interest in infrastructure investments as a low-cost funding source.
- Evolving Market Dynamics: The attractiveness of North American energy assets has surged as Middle Eastern energy supplies have been throttled due to the U.S.-Iran conflict, increasing the number of potential buyers for the LNG Canada project and intensifying the bidding competition, highlighting a market preference for low-risk, long-duration investments.
See More
EXCLUSIVE: APOLLO, BLACKSTONE, AND KKR EMERGE AS FINAL CONTENDERS TO PURCHASE SHELL'S STAKE IN LNG CANADA, SOURCES REVEAL
Acquisition Details: Blackstone and KKR are final bidders in a race to acquire a stake in LNG Canada from Shell.
Market Implications: This acquisition reflects ongoing interest and investment in the liquefied natural gas sector.
See More
India's IT Sector Faces Employment Crisis Amid AI Disruption
- Deepening Employment Crisis: Bernstein warns that the rise of AI may lead to a reduction in high-quality jobs in India's IT sector, affecting the income and consumption capacity of 10 to 15 million employees in IT services and outsourcing, thereby threatening the foundation of national economic growth.
- Shifting Hiring Trends: Net hiring by India's top five IT companies dropped by around 7,000 in FY26, with TCS planning to hire only 25,000 fresh graduates compared to an average of 40,000 over the past three years, indicating a diminishing reliance on large-scale recruitment in the industry.
- Skills Gap Challenge: While the Indian government emphasizes
See More
Blackstone's $400 Million Investment in Teva: A Strategic Bet
- Investment Scale and Strategic Significance: Blackstone Life Sciences' $400 million investment in Teva Pharmaceuticals in March 2023 reflects strong confidence in the new drug duvakitug, representing not just financial backing but a significant bet on Teva's future development.
- Drug Potential and Clinical Progress: Duvakitug, a monoclonal antibody targeting TL1A, is currently undergoing Phase 3 clinical trials for ulcerative colitis and Crohn's disease, with promising Phase 2 results showing durable efficacy over 44 weeks, indicating a broad market potential.
- Teva's Transformation and Market Recognition: Teva has evolved from a mere generic drug manufacturer to a leader in biopharmaceutical innovation, with credit rating agencies upgrading its rating to BB+, reflecting market confidence in its transformation.
- Opportunities and Risks for Investors: Blackstone's investment not only provides Teva with financial support but may also yield milestone payments and low single-digit royalties on global sales, suggesting that while risk-averse investors might hesitate, aggressive investors could find significant value in Teva, especially if duvakitug succeeds as anticipated.
See More
Blackstone Commits $400 Million to Teva's Drug Development
- Significant Investment: Blackstone Life Sciences has committed $400 million to Teva Pharmaceuticals to support the development of its autoimmune disease drug, duvakitug, reflecting confidence in Teva's future and showcasing Blackstone's strategic positioning in the biopharmaceutical sector.
- Clinical Trial Progress: Duvakitug is currently undergoing Phase 3 clinical trials aimed at treating ulcerative colitis and Crohn's disease, with promising Phase 2 results indicating durable efficacy over 44 weeks, suggesting substantial market potential and the possibility of becoming a best-in-class therapy.
- Credit Rating Upgrade: Following Blackstone's investment, credit rating agencies have begun to recognize Teva's turnaround, with S&P Global upgrading Teva's credit rating from BB to BB+ in December 2025, reflecting a stable outlook and market optimism about its future development.
- Positive Market Outlook: Analysts are generally bullish on Teva, with 12 out of 13 surveyed analysts rating the stock as a
See More
Shell Sells Stake in LNG Canada Project Amid Bidding War
- Bidding War Intensifies: Apollo Global Management, Blackstone, and KKR are competing to acquire a significant stake in Shell's LNG Canada project, with the deal expected to be valued well over $10 billion, potentially reaching $15 billion, indicating strong market interest in LNG projects.
- Shell's Strategic Shift: The sale will allow Shell to divest a portion of its 40% stake in LNG Canada while funding its $16.4 billion acquisition of Canadian natural gas producer ARC Resources, thereby optimizing its asset portfolio.
- Significant Market Potential: The LNG Canada project, which began production in June, is the first major liquefied natural gas facility in North America with direct access to the Pacific, enabling direct shipments to Asia, the largest market for super-cooled fuel, and is expected to attract more investor attention.
- Clear Transaction Structure: Shell plans to sell both the first and second phases of the project to a single bidder rather than splitting them, a strategy that will help streamline the transaction process and enhance buyer confidence.
See More
Apollo, Blackstone, KKR Compete for LNG Canada Stake
- Bidding Landscape: Apollo, Blackstone, and KKR are competing to acquire a 40% stake in Shell's LNG Canada project, with the deal expected to be valued well above $10 billion and potentially reaching $15 billion, providing Shell with crucial capital to support its expansion plans.
- Strategic Implications: The sale will allow Shell to focus on higher-return businesses after its $16.4 billion acquisition of Canadian natural gas producer ARC Resources, while attracting new capital to further develop the LNG project, enhancing its competitive position in the North American market.
- Insurance Capital Utilization: All three firms are leveraging capital from their insurance businesses—Apollo's Athene, Blackstone Credit & Insurance, and KKR's Global Atlantic—to bolster their bids, reflecting the asset management industry's ongoing interest in infrastructure investments as a low-cost funding source.
- Evolving Market Dynamics: The attractiveness of North American energy assets has surged as Middle Eastern energy supplies have been throttled due to the U.S.-Iran conflict, increasing the number of potential buyers for the LNG Canada project and intensifying the bidding competition, highlighting a market preference for low-risk, long-duration investments.
See More
EXCLUSIVE: APOLLO, BLACKSTONE, AND KKR EMERGE AS FINAL CONTENDERS TO PURCHASE SHELL'S STAKE IN LNG CANADA, SOURCES REVEAL
Acquisition Details: Blackstone and KKR are final bidders in a race to acquire a stake in LNG Canada from Shell.
Market Implications: This acquisition reflects ongoing interest and investment in the liquefied natural gas sector.
See More
India's IT Sector Faces Employment Crisis Amid AI Disruption
- Deepening Employment Crisis: Bernstein warns that the rise of AI may lead to a reduction in high-quality jobs in India's IT sector, affecting the income and consumption capacity of 10 to 15 million employees in IT services and outsourcing, thereby threatening the foundation of national economic growth.
- Shifting Hiring Trends: Net hiring by India's top five IT companies dropped by around 7,000 in FY26, with TCS planning to hire only 25,000 fresh graduates compared to an average of 40,000 over the past three years, indicating a diminishing reliance on large-scale recruitment in the industry.
- Skills Gap Challenge: While the Indian government emphasizes
See More
